SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001764013-22-000139
Filing Date
2022-11-04
Accepted
2022-11-04 07:15:44
Documents
13
Period of Report
2022-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imvt-20221104.htm   iXBRL 8-K 35499
2 EX-99.1 exhibit99120221104.htm EX-99.1 79988
  Complete submission text file 0001764013-22-000139.txt   259919

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imvt-20221104.xsd EX-101.SCH 1896
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imvt-20221104_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imvt-20221104_pre.xml EX-101.PRE 12504
7 EXTRACTED XBRL INSTANCE DOCUMENT imvt-20221104_htm.xml XML 10819
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

IRS No.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38906 | Film No.: 221360174
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences